RUNX2 interacts with SCD1 and activates Wnt/β-catenin signaling pathway to promote the progression of clear cell renal cell carcinoma.
Xiandong SongJunlong LiuBitian LiuChiyuan PiaoChuize KongZhenhua LiPublished in: Cancer medicine (2022)
The findings indicate that the RUNX2/SCD1 axis may act as a potential therapeutic target via the Wnt/β-catenin signaling pathway of ccRCC.